Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant

International Journal of Pharmaceutics

Volumn 356, Issue 1-2, 2008, Pages 110-120

  Matthews, K H ^a   Stevens, H N E ^a   Auffret, A D ^b   Humphrey, M J ^b   Eccleston, G M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Lyophilised wafer; Stability; Surfactant; Thermal analysis; UK 370,106; Wound healing

Indexed keywords

STROMELYSIN INHIBITOR; UK 370 106;

ARTICLE; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; PRIORITY JOURNAL; THERMAL ANALYSIS; THERMOGRAVIMETRY; WOUND HEALING;

CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; DRUG STORAGE; ENZYME INHIBITORS; FREEZE DRYING; GELS; HEXANOIC ACIDS; MATRIX METALLOPROTEINASE 3; PARTICLE SIZE; POLOXAMER; POLYSACCHARIDES, BACTERIAL; SOLUBILITY; SURFACE-ACTIVE AGENTS; VALINE; WOUND HEALING;

EID: 42649136548     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.12.043     Document Type: Article

References (36)

1. Alexandridis P., and Hatton T.A. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modelling. Colloid Surf. A: Physicochem. Eng. Aspects 96 (1995) 1-46
2. Ashcroft C.P., Challenger S., Derrick A.M., Storey R., and Thomson N.M. Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif. Org. Process Res. Dev. 7 (2003) 362-368
3. Bird, J., Montana, J.G., Wills, R.E., Baxter, A.D., Owen, D.A., 1998. Selective MMP-3 inhibitors having reduced side-effects. International Patent. Darwin Discovery Ltd., WO 9,839,024, November 09.
4. Cai S.S., Liu Y.C., Shu X.Z., and Prestwich G.D. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26 (2005) 6054-6067
5. DeFail A.J., Chu C.R., Izzo N., and Marra K.G. Controlled release of bioactive TGF-beta(1) from microspheres embedded within biodegradable hydrogels. Biomaterials 27 (2006) 1579-1585
6. Desiraju G.R. Crystal or co-crystal. Cryst. Eng. Commun. 5 (2003) 466-467
7. Draye J.P., Delaey B., Van de Voorde A., Van den Bulcke A., Bogdanov B., and Schacht E. In vitro release characteristics of bioactive molecules from dextran dialdehyde cross-linked hydrogel films. Biomaterials 19 (1998) 99-107
8. Fray M.J., and Dickinson R.P. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloproteinase-3 (stromelysin-1). Bioorg. Med. Chem. Lett. 11 (2001) 571-574
9. Fray M.J., Burslem M.F., and Dickinson R.P. Selectivity of inhibition of matrix metalloproteinase MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3′ group chirality. Bioorg. Med. Chem. Lett. 11 (2001) 567-570
10. Fray M.J., Dickinson R.P., Huggins J.P., and Occleston N.L. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J. Med. Chem. 46 (2003) 3514-3525
11. Gombotz W.R., and Wee S.F. Protein release from alginate matrices. Adv. Drug. Deliv. Rev. 31 (1998) 267-285
12. Gryzybowski J., Oldak E., Antos-Bielska M., Janiak M.K., and Pojda Z. New cytokine dressing. I. Kinetics of the in vitro rhG-CSF, rhGM-CSF and rhEGF release from the dressings. Int. J. Pharm. 184 (1999) 173-178
13. Guzman-Gardearzabal E., Leyva-Bohorquez G., Sala-Coiln S., Paz-Janeiro J.L., Alvarado-Ruiz R., and Garcia-Salazar R. Treatment of chronic ulcers in the lower extremeties with topical becaplermin gel 0.01%: a multicenter open-label study. Adv. Ther. 17 (2000) 184-189
14. Hubbell J.A. Hydrogel systems for barriers and local drug delivery in the control of woundhealing. J. Contr. Release 39 (1996) 305-313
15. Kibbe A.H. Handbook of Pharmaceutical Excipients. 3rd ed. (2000), Pharmaceutical Press, London
16. Maskarinec S.A., Hannig J., Lee R.C., and Lee K.Y.C. Direct observation of Poloxamer 188 insertion into lipid monolayers. Biophys. J. 82 (2002) 1453-1459
17. Masters K.S.B., Leibovich S.J., Belem P., West J.L., and Poole-Warren L.A. Effects of nitric oxide releasing poly(vinyl alcohol) hydrogel dressings on dermal wound healing in diabetic mice. Wound Repair Regen. 10 (2002) 286-294
18. Matthews, K.H., Stevens, H.N.E., Auffret, A.D., Humphrey, M.J., Eccleston, G.M., 2003. Wafer for wounds. International Patent. Pfizer Ltd., WO 03,037,395, August 05.
19. Matthews K.H., Stevens H.N.E., Auffret A.D., Humphrey M.J., and Eccleston G.M. Lyophilised wafers as a drug delivery system for wound healing containing methylcellulose as a viscosity modifier. Int. J. Pharm. 289 (2005) 51-62
20. Matthews K.H., Stevens H.N.E., Auffret A.D., Humphrey M.J., and Eccleston G.M. Gamma-irradiation of lyophilised wound healing wafers. Int. J. Pharm. 313 (2006) 78-86
21. McInnes F.J., Thapa P., Baillie A.J., Welling P.G., Watson D.G., Gibson I., Nolan A., and Stevens H.N.E. In vivo evaluation of nicotine lyophilised nasal insert in sheep. Int. J. Pharm. 304 (2005) 72-82
22. Mullin J.W. Crystallisation. 4th ed. (2001), Elsevier
23. Nichols G., Byard S., Bloxham M.J., Botterill J., Dawson N.J., Dennis A., Diart A., North N.C., and Sherwood J.D. A review of the terms agglomerate and aggregate with a recommendation for nomenclature used in powder and particle characterisation. J. Pharm. Sci. 91 (2002) 2103-2109
24. Obara K., Ishihara M., Ishizuka T., Fujita M., Ozeki Y., Maehara T., Saito Y., Yura H., Matsui T., Hattori H., Kikuchi M., and Kurita A. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 24 (2003) 3437-3444
25. Ono I., Tateshita T., and Iniue M. Effects of collagen matrix containing basic fibroblast growth factor on wound contraction. J. Biomed. Mater. Res. 48 (1999) 621-630
26. Puolakkainen P.A., Twardzik D.R., and Ranchalis J.E. The enhancement in wound healing by transforming growth factor-beta (1) (TGF-beta(1)) depends on the topical delivery system. J. Surg. Res. 58 (1995) 321-329
27. Saarialho-Kere U.K., Kovacs S.O., and Pentland A.P. Cell matrix interaction modulated interstitial collagenase expression by human keratinocytes actively involved in wound healing. J. Clin. Invest. 92 (1993) 2858-2866
28. Sakiyama-Elbert S.E., and Hubbell J.A. Controlled release of nerve growth factors from a heparin-containing fibrin-based cell ingrowth matrix. J. Control Release 69 (2000) 149-158
29. Salo T., Makanen M., Kylmaniemi M., Autio-Harmainen H., and Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab. Invest. 70 (1994) 176-182
30. Skakle J.M.S., Wardle J.L., Low J.N., and Glidewell C. Solvated and solvent-free forms of N,N′-dithiodiphthalimide. Acta Cryst. C57 (2001) 724-746
31. Suitchmezian V., Jess I., and Nather C. Crystal structures and properties of two new pseudopolymorphic modifications of the glucocorticoide triamcinolone diacetate. Solid State Sci. 8 (2006) 1373-1379
32. Takino T., Sato H., Shinagawa A., and Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270 (1995) 23013-23020
33. Thomas S., Fear M., Humphreys J., Disley L., and Waring M.J. The effects of dressings on the production of exudates from venous leg ulcers. Wounds 8 (1996) 145-149
34. Vaalamo M., Mattila L., Johansson N., Kariniemi A.L., Karjalainen-Lindsberg M.L., Kahari V.M., and Saarialho-Kere U.K. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chroninc ulcers but not in normally healing wounds. J. Invest. Dermatol. 109 (1997) 96-101
35. Yamaguchi Y., and Yoshikawa K. Cutaneous wound healing-an update. J. Dermatol. 28 (2001) 521-534
36. Yamamoto M., Ikada Y., and Tabata Y. Controlled release of growth factors based on biodegradation of gelatin hydrogel. J. Biomater. Sci.-Polym. Ed. 12 (2001) 77-88